{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination induces a type I interferon response in tumours.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors",
          "line_ref": "L31"
        },
        {
          "quote": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.",
          "line_ref": "L42"
        }
      ],
      "caveat": "This report summarizes mechanistic induction primarily from tumour measurements and proposed chain; strength may vary by model system."
    },
    {
      "claim_id": "C02",
      "claim": "Intratumoral mRNA vaccination broadens antigen presentation, including expansion of the MHC-I peptidome.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination",
          "line_ref": "L28"
        },
        {
          "quote": "Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape",
          "line_ref": "L29"
        },
        {
          "quote": "A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.",
          "line_ref": "L44"
        }
      ],
      "caveat": "These quantitative peptidome fractions are reported as preclinical readouts and may not directly translate to clinical tumour antigen presentation breadth."
    },
    {
      "claim_id": "C03",
      "claim": "The combined strategy (intratumoral mRNA vaccination plus anti-PD-L1) improves tumour control in mice and is consistent with improved outcomes in a retrospective human cohort.",
      "strength": "tentative",
      "evidence": [
        {
          "quote": "Preclinical arm: multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations.",
          "line_ref": "L14"
        },
        {
          "quote": "Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.",
          "line_ref": "L46"
        },
        {
          "quote": "Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment",
          "line_ref": "L30"
        }
      ],
      "caveat": "The human evidence is explicitly retrospective and non-randomized, so the alignment with better outcomes cannot establish causality for vaccination improving ICI response."
    },
    {
      "claim_id": "C04",
      "claim": "The sensitization benefit depends on type I interferon signaling, because IFNAR1 blockade eliminates the effect.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.",
          "line_ref": "L39"
        },
        {
          "quote": "Interferon-associated antigen processing and presentation pathways increase.",
          "line_ref": "L43"
        }
      ],
      "caveat": "Elimination of benefit with IFNAR1 blockade is a mechanistic control within the tested models; it does not prove the same dependency in all tumour types or in patients."
    },
    {
      "claim_id": "C05",
      "claim": "The retrospective human comparison is vulnerable to confounding and is not sufficient for direct causal interpretation.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "The human analysis is retrospective and non-randomized; residual confounding is likely.",
          "line_ref": "L49"
        },
        {
          "quote": "Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.",
          "line_ref": "L51"
        }
      ],
      "caveat": "Despite these limitations, the analysis may still be hypothesis-generating for prospective trial design rather than definitive evidence of benefit."
    }
  ]
}
